Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, CANADA.
Department of Community Health Sciences, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, CANADA.
Inflamm Bowel Dis. 2021 Jul 27;27(8):1285-1293. doi: 10.1093/ibd/izaa349.
We aimed to examine associations between elevated symptoms of depression and anxiety and disease activity in inflammatory bowel disease (IBD). Previous findings have been inconsistent and have not accounted for variability in the courses of these conditions over time.
We followed 247 participants with IBD (153 Crohn's disease [CD], 94 ulcerative colitis [UC]) for 3 years. Annually, participants underwent an abdominal examination, reported therapies used for IBD, and completed the Hospital Anxiety and Depression Scale (HADS) questionnaire. We evaluated associations of elevated symptoms (scores ≥11) of anxiety (HADS-A) and depression (HADS-D) with the presence of active IBD as measured using the Powell Tuck Index for UC and the Harvey-Bradshaw Disease Activity Index for CD. We employed logistic regression with generalized estimating equations, simultaneously estimating between-person and within-person effects.
Of 247 participants, 15 (6.1%) had elevated symptoms of depression (HADS-D ≥11) at enrollment, 41 (16.6%) had elevated symptoms of anxiety (HADS-A ≥11), and 101 (40.9%) had active IBD. On average, individuals with elevated symptoms of depression (odds ratio [OR], 6.27; 95% CI, 1.39-28.2) and anxiety (OR, 2.17; 95% CI, 1.01-4.66) had increased odds of active IBD. Within individuals, elevations in symptoms of depression over time were associated with increased odds of active IBD (OR, 2.70; 95% CI, 1.15-6.34), but elevated symptoms of anxiety were not. After adjustment for covariates (including disease activity), elevated symptoms of depression were also associated with increased odds of biologic therapy use (OR, 2.02; 95% CI, 1.02-4.00).
Symptoms of depression and anxiety are associated with disease activity in IBD over time. Reducing these symptoms should be incorporated into the management of IBD.
我们旨在研究炎症性肠病(IBD)患者中抑郁和焦虑症状升高与疾病活动之间的关系。先前的研究结果不一致,并且没有考虑到这些疾病随时间变化的过程中的变异性。
我们对 247 名 IBD 患者(153 例克罗恩病[CD],94 例溃疡性结肠炎[UC])进行了 3 年的随访。每年,参与者接受腹部检查,报告用于治疗 IBD 的药物,并完成医院焦虑和抑郁量表(HADS)问卷。我们评估了焦虑(HADS-A)和抑郁(HADS-D)症状升高(评分≥11)与 UC 的 Powell Tuck 指数和 CD 的 Harvey-Bradshaw 疾病活动指数测量的活动性 IBD 之间的关联。我们采用了具有广义估计方程的逻辑回归,同时估计个体间和个体内的效应。
在 247 名参与者中,15 名(6.1%)在入组时出现抑郁症状升高(HADS-D≥11),41 名(16.6%)出现焦虑症状升高(HADS-A≥11),101 名(40.9%)存在活动性 IBD。平均而言,抑郁症状升高的个体(比值比[OR],6.27;95%置信区间[CI],1.39-28.2)和焦虑症状升高的个体(OR,2.17;95%CI,1.01-4.66)具有更高的活动性 IBD 的可能性。在个体内,随着时间的推移,抑郁症状的升高与活动性 IBD 的可能性增加相关(OR,2.70;95%CI,1.15-6.34),但焦虑症状的升高则没有。在调整了协变量(包括疾病活动度)后,抑郁症状升高也与生物治疗的使用几率增加相关(OR,2.02;95%CI,1.02-4.00)。
抑郁和焦虑症状与 IBD 的疾病活动随时间相关。降低这些症状应该被纳入 IBD 的管理中。